The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation

Josh Levitsky*, R. N. Formica, R. D. Bloom, M. Charlton, M. Curry, John J Friedewald, J. Friedman, D. Goldberg, S. Hall, Michael G Ison, T. Kaiser, D. Klassen, G. Klintmalm, J. Kobashigawa, A. Liapakis, K. O'Conner, P. Reese, D. Stewart, N. Terrault, N. TheodoropoulosJ. Trotter, E. Verna, M. Volk

*Corresponding author for this work

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection has resulted in a profound shift in the approach to the management of this infection. These changes have affected the practice of solid organ transplantation by altering the framework by which patients with end-stage organ disease are managed and receive organ transplants. The high level of safety and efficacy of these medications in patients with chronic HCV infection provides the opportunity to explore their use in the setting of transplanting organs from HCV-viremic patients into non–HCV-viremic recipients. Because these organs are frequently discarded and typically come from younger donors, this approach has the potential to save lives on the solid organ transplant waitlist. Therefore, an urgent need exists for prospective research protocols that study the risk versus benefit of using organs for hepatitis C–infected donors. In response to this rapidly changing practice and the need for scientific study and consensus, the American Society of Transplantation convened a meeting of experts to review current data and develop the framework for the study of using HCV viremic organs in solid organ transplantation.

Original languageEnglish (US)
Pages (from-to)2790-2802
Number of pages13
JournalAmerican Journal of Transplantation
Volume17
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Organ Transplantation
Hepatitis C
Hepacivirus
Tissue Donors
Virus Diseases
Transplants
Chronic Hepatitis C
Hepatitis
Antiviral Agents
Safety
Infection
Research
Therapeutics

Keywords

  • clinical decision-making
  • clinical research/practice
  • clinical trial design
  • donors and donation: donor-derived infections
  • education
  • infection and infectious agents
  • organ allocation
  • organ procurement and allocation
  • organ transplantation in general
  • viral: hepatitis C

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Levitsky, Josh ; Formica, R. N. ; Bloom, R. D. ; Charlton, M. ; Curry, M. ; Friedewald, John J ; Friedman, J. ; Goldberg, D. ; Hall, S. ; Ison, Michael G ; Kaiser, T. ; Klassen, D. ; Klintmalm, G. ; Kobashigawa, J. ; Liapakis, A. ; O'Conner, K. ; Reese, P. ; Stewart, D. ; Terrault, N. ; Theodoropoulos, N. ; Trotter, J. ; Verna, E. ; Volk, M. / The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. In: American Journal of Transplantation. 2017 ; Vol. 17, No. 11. pp. 2790-2802.
@article{f59832005e3c4e119ad7690105ae5151,
title = "The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation",
abstract = "The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection has resulted in a profound shift in the approach to the management of this infection. These changes have affected the practice of solid organ transplantation by altering the framework by which patients with end-stage organ disease are managed and receive organ transplants. The high level of safety and efficacy of these medications in patients with chronic HCV infection provides the opportunity to explore their use in the setting of transplanting organs from HCV-viremic patients into non–HCV-viremic recipients. Because these organs are frequently discarded and typically come from younger donors, this approach has the potential to save lives on the solid organ transplant waitlist. Therefore, an urgent need exists for prospective research protocols that study the risk versus benefit of using organs for hepatitis C–infected donors. In response to this rapidly changing practice and the need for scientific study and consensus, the American Society of Transplantation convened a meeting of experts to review current data and develop the framework for the study of using HCV viremic organs in solid organ transplantation.",
keywords = "clinical decision-making, clinical research/practice, clinical trial design, donors and donation: donor-derived infections, education, infection and infectious agents, organ allocation, organ procurement and allocation, organ transplantation in general, viral: hepatitis C",
author = "Josh Levitsky and Formica, {R. N.} and Bloom, {R. D.} and M. Charlton and M. Curry and Friedewald, {John J} and J. Friedman and D. Goldberg and S. Hall and Ison, {Michael G} and T. Kaiser and D. Klassen and G. Klintmalm and J. Kobashigawa and A. Liapakis and K. O'Conner and P. Reese and D. Stewart and N. Terrault and N. Theodoropoulos and J. Trotter and E. Verna and M. Volk",
year = "2017",
month = "11",
day = "1",
doi = "10.1111/ajt.14381",
language = "English (US)",
volume = "17",
pages = "2790--2802",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "11",

}

Levitsky, J, Formica, RN, Bloom, RD, Charlton, M, Curry, M, Friedewald, JJ, Friedman, J, Goldberg, D, Hall, S, Ison, MG, Kaiser, T, Klassen, D, Klintmalm, G, Kobashigawa, J, Liapakis, A, O'Conner, K, Reese, P, Stewart, D, Terrault, N, Theodoropoulos, N, Trotter, J, Verna, E & Volk, M 2017, 'The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation', American Journal of Transplantation, vol. 17, no. 11, pp. 2790-2802. https://doi.org/10.1111/ajt.14381

The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. / Levitsky, Josh; Formica, R. N.; Bloom, R. D.; Charlton, M.; Curry, M.; Friedewald, John J; Friedman, J.; Goldberg, D.; Hall, S.; Ison, Michael G; Kaiser, T.; Klassen, D.; Klintmalm, G.; Kobashigawa, J.; Liapakis, A.; O'Conner, K.; Reese, P.; Stewart, D.; Terrault, N.; Theodoropoulos, N.; Trotter, J.; Verna, E.; Volk, M.

In: American Journal of Transplantation, Vol. 17, No. 11, 01.11.2017, p. 2790-2802.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation

AU - Levitsky, Josh

AU - Formica, R. N.

AU - Bloom, R. D.

AU - Charlton, M.

AU - Curry, M.

AU - Friedewald, John J

AU - Friedman, J.

AU - Goldberg, D.

AU - Hall, S.

AU - Ison, Michael G

AU - Kaiser, T.

AU - Klassen, D.

AU - Klintmalm, G.

AU - Kobashigawa, J.

AU - Liapakis, A.

AU - O'Conner, K.

AU - Reese, P.

AU - Stewart, D.

AU - Terrault, N.

AU - Theodoropoulos, N.

AU - Trotter, J.

AU - Verna, E.

AU - Volk, M.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection has resulted in a profound shift in the approach to the management of this infection. These changes have affected the practice of solid organ transplantation by altering the framework by which patients with end-stage organ disease are managed and receive organ transplants. The high level of safety and efficacy of these medications in patients with chronic HCV infection provides the opportunity to explore their use in the setting of transplanting organs from HCV-viremic patients into non–HCV-viremic recipients. Because these organs are frequently discarded and typically come from younger donors, this approach has the potential to save lives on the solid organ transplant waitlist. Therefore, an urgent need exists for prospective research protocols that study the risk versus benefit of using organs for hepatitis C–infected donors. In response to this rapidly changing practice and the need for scientific study and consensus, the American Society of Transplantation convened a meeting of experts to review current data and develop the framework for the study of using HCV viremic organs in solid organ transplantation.

AB - The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection has resulted in a profound shift in the approach to the management of this infection. These changes have affected the practice of solid organ transplantation by altering the framework by which patients with end-stage organ disease are managed and receive organ transplants. The high level of safety and efficacy of these medications in patients with chronic HCV infection provides the opportunity to explore their use in the setting of transplanting organs from HCV-viremic patients into non–HCV-viremic recipients. Because these organs are frequently discarded and typically come from younger donors, this approach has the potential to save lives on the solid organ transplant waitlist. Therefore, an urgent need exists for prospective research protocols that study the risk versus benefit of using organs for hepatitis C–infected donors. In response to this rapidly changing practice and the need for scientific study and consensus, the American Society of Transplantation convened a meeting of experts to review current data and develop the framework for the study of using HCV viremic organs in solid organ transplantation.

KW - clinical decision-making

KW - clinical research/practice

KW - clinical trial design

KW - donors and donation: donor-derived infections

KW - education

KW - infection and infectious agents

KW - organ allocation

KW - organ procurement and allocation

KW - organ transplantation in general

KW - viral: hepatitis C

UR - http://www.scopus.com/inward/record.url?scp=85021665485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021665485&partnerID=8YFLogxK

U2 - 10.1111/ajt.14381

DO - 10.1111/ajt.14381

M3 - Article

C2 - 28556422

AN - SCOPUS:85021665485

VL - 17

SP - 2790

EP - 2802

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 11

ER -